Of the three presentations in the Resverlogix sponsored session at ESC16, only the presentation by J. Kastelein dealt directly with RVX-208.

The abstract from the presentation by J. Kastelein reads as follows (sorry for any typos):

BET inhibition in cardiovascular disease: A new dawn?

Bromodoamin and Extra-Terminal domain (BET) proteins are epigenetic readers of chromatin associated histones. Apabetalone (RVX-208) is a selective inhibitor of BET proteins. BET inhibition (BETi) modulates multiple biological pathhways that underlie cardiovascular disease (CVD) risks. For example, in patients with CVD, BETi affects the following pathways: (i) reduces vascular inflammation, (II) modulates complement and coagulation, (iii) enhances reverse cholesterol transport, and (iv) beneficially modulates metabolism. Results from three Phase 2b trials of CVD patients (n=798) show changes in biomarkes of CVD reflective of the in vitro actions of apabetalone on gene expression. Additionally, post hoc analysis of the preceding studies revealed that apabetalone reduced overall major adverse cardiovascular events (MACE) in patients, with more pronounced reductions in those with low level of HDL, elevated CRP or diabetes mellitus (DM) comorbidities. These findings form the foundation of the ongoing phase 3 (BETonMACE, a large international multi-center, double-blind, randomized, parallel group, placebo-controlled trial) study in post-ACS patients with DM and low HDL. The primary objective of the BETonMACE study is to show a relative risk reduction of three point MACE, defined as CV death, non-fatal myocardial infarction and stroke.

-----

I did not attend the conference, but I know from a cardiologist who did that it came across as promising yet very complex.

/B